DOXORUBICIN AND GEMCITABINE IN CANCER THERAPY: CLASSIFICATION, MECHANISMS, LIMITATIONS, AND MODERN DELIVERY APPROACHES

This article examines the current classification of chemotherapeutic agents and the role of Doxorubicin and Gemcitabine in oncology therapy. The mechanisms of action, therapeutic efficacy, and major limitations of these drugs are analyzed, including nonspecific toxicity and the development of drug resistance in tumor cells. Particular attention is given to modern approaches aimed at reducing adverse effects, such as targeted drug delivery systems and the use of nanocarriers that enable selective accumulation of chemotherapeutic agents in tumor tissue. Furthermore, the prospects for the development of chemotherapy are discussed, including combination treatment regimens and personalized therapeutic strategies designed to improve clinical outcomes and safety. This study emphasizes the importance of further research to optimize the therapeutic application of doxorubicin and gemcitabine in cancer treatment.